How a planetarium show discovered a spiral at the edge of our solar system
'So this is a really fun thing that happened,' says Jackie Faherty, the museum's senior scientist.
Last winter, Faherty and her colleagues were beneath the dome of the museum's Hayden Planetarium, fine-tuning a scene that featured the Oort cloud, the big, thick bubble surrounding our Sun and planets that's filled with ice and rock and other remnants from the solar system's infancy. The Oort cloud begins far beyond Neptune, around one and a half light years from the Sun. It has never been directly observed; its existence is inferred from the behavior of long-period comets entering the inner solar system. The cloud is so expansive that the Voyager spacecraft, our most distant probes, would need another 250 years just to reach its inner boundary; to reach the other side, they would need about 30,000 years.
The 30-minute show, Encounters in the Milky Way,
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Existing NASA Spacecraft Could Intercept the Weird Interstellar Object Cruising Into Our Star System
Earlier this month, astronomers noticed a mysterious object speeding toward the inner solar system from outside of our star system. It's an exceedingly rare occurrence, marking only the third confirmed interstellar object to have ventured into our solar system, all of which have been detected since 2017. Harvard astronomer and alien hunter Avi Loeb was quick to raise the tantalizing — albeit admittedly far-fetched — possibility that the object, dubbed 3I/ATLAS, could have been an alien probe sent to us by an intelligent civilization. And now, in a twist right out of Stanley Kubrick's 1968 "2001: A Space Odyssey," he's suggesting a way that we could use an existing spacecraft to intercept the object's path to test that very hypothesis. In a yet-to-be-peer-reviewed paper, the researcher argued that NASA's Juno spacecraft, which was designed to study Jupiter and launched in 2011, could get eerily close to 3I/ATLAS by March 14, 2026. Juno would have to apply a thrust of 1.66 miles per second on September 14, 2025, Loeb calculated, to intercept the mysterious object's path. "The close encounter of 3I/ATLAS to Jupiter provides a rare opportunity to shift Juno from its current orbit around Jupiter to intercept the path of 3I/ATLAS at its closest approach to Jupiter," he wrote in a new blog post about the proposal. While it's technically not a rendezvous — the object's "excessively high hyperbolic speed" wouldn't allow for such a meeting — Juno's arsenal of scientific instruments "can all be used to probe the nature of 3I/ATLAS from a close distance," Loeb argued. Whether the spacecraft, which has been soaring through space for 14 years now, would have enough fuel to even pull off such a stunt remains unclear. But Loeb argues it could "rejuvenate Juno's mission and extend its scientific lifespan beyond" the potential intercept some eight months from now. The news comes as scientists are still racing to get a better sense of 3I/ATLAS' exact nature. Last week, the recently inaugurated Vera C. Rubin Observatory in Chile had a closer look, finding that the object is roughly seven miles wide, making it the largest interstellar object ever spotted. The prevailing and most widely accepted theory suggests that 3I/ATLAS is a comet, with previous observations supporting the idea that its coma, or surrounding cloud of ice, dust, and gas, was anywhere up to 15 miles across. The Vera C. Rubin observations identified large amounts of dust and water ice surrounding its solid nucleus, as detailed in a July 17 preprint, further adding evidence that it's a comet. Yet many questions surrounding its origin remain a mystery. Some researchers believe it came from our galaxy's "thick disk," a dense layer that features chemically distinct populations of stars. Other researchers suggest it could be around three to 11 billion years old, dating it back to the earliest days of the Milky Way. It seems unlikely that NASA will find Loeb's suggestion compelling enough to fire up Juno's thrusters for an intercept. But it's an extremely rare opportunity to finally get a close glimpse of an interstellar visitor nonetheless — so hopefully they're at least checking his math to see if it's possible. More on 3I/ATLAS: Scientist Suggests Tests to See if Large Object Headed Toward Earth Could Be an Alien Spacecraft Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Moon phase today: What the moon will look like on July 29, 2025
We're well and truly into the new lunar cycle, and the moon is starting to appear more visible to us on Earth. So, what's happening tonight, July 29? What is today's moon phase? As of Tuesday, July 29, the moon phase is Waxing Crescent. There's 23% of the moon's surface visible to us on Earth (according to NASA's Daily Moon Observation). It's the fifth day of the lunar cycle, and there is plenty to see tonight. With the unaided eye, enjoy a glimpse of the Mare Crisium and the Mare Fecunditatis, an impact basin also known as the "Sea of Fertility." Add binoculars or a telescope, and you'll see the Endymion Crater too. When is the next full moon? The next full moon will be on August 9. The last full moon was on July 10. What are moon phases? According to NASA, moon phases are caused by the 29.5-day cycle of the moon's orbit, which changes the angles between the Sun, Moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. This is how we get full moons, half moons, and moons that appear completely invisible. There are eight main moon phases, and they follow a repeating cycle: New Moon - The moon is between Earth and the sun, so the side we see is dark (in other words, it's invisible to the eye). Waxing Crescent - A small sliver of light appears on the right side (Northern Hemisphere). First Quarter - Half of the moon is lit on the right side. It looks like a half-moon. Waxing Gibbous - More than half is lit up, but it's not quite full yet. Full Moon - The whole face of the moon is illuminated and fully visible. Waning Gibbous - The moon starts losing light on the right side. Last Quarter (or Third Quarter) - Another half-moon, but now the left side is lit. Waning Crescent - A thin sliver of light remains on the left side before going dark again. Solve the daily Crossword
Medscape
4 hours ago
- Medscape
Dupilumab Controls Cancer Rx-Related Skin Toxicities
TOPLINE: Patients with antibody-drug conjugate (ADC)-related skin reactions had higher response rates and fewer treatment discontinuations when treated with dupilumab than with systemic steroids. METHODOLOGY: Researchers evaluated 163 patients at Memorial Sloan Kettering Cancer Center who received an ADC from January 2020 through September 2024, with follow-up until December 2024. The analysis included 27 adult patients with ADC-induced dermatologic adverse events (dAEs); 11 were treated with dupilumab (63.6% women; 81.8% White) and 16 were treated with systemic steroids alone (37.5% women; 81.2% White). Researchers analyzed the severity of dAEs, treatment responses, and cancer treatment discontinuation rates. TAKEAWAY: In the dupilumab group, 82% of patients received enfortumab vedotin for genitourinary malignancies, and 46% received pembrolizumab. Clinical presentations of dAEs included eczematous eruptions in 54% of patients, morbilliform eruptions in 46%, and vesiculobullous eruptions in 27%. In the steroid-treated group, all patients received enfortumab vedotin with pembrolizumab for genitourinary malignancies. In the dupilumab group, 70% of patients experienced grade 3 events, whereas 56% in the steroid-only group experienced grade 2 reactions. In the dupilumab group vs the steroid-only group, 73% vs 56% of patients achieved complete response, and 27% vs 25% achieved partial response of skin reactions, respectively. Among those on dupilumab, the median time to first clinical response was 24 days, and the median time to best clinical response was 52 days. In the dupilumab group, no patients discontinued treatment because of dAEs vs 43.8% in the steroid-only group (P < .05). IN PRACTICE: 'Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,' which 'are difficult to manage and can disrupt cancer treatment,' the study authors wrote. 'Further research is essential to explore its broader utility and economic feasibility,' they added. SOURCE: The study was led by Ian Nykaza, BS, of the Dermatology Service, Department of Medicine at Memorial Sloan Kettering Cancer Center, New York City. It was published online on July 30 in JAMA Dermatology. LIMITATIONS: Limitations included the small study size, retrospective design, treatment heterogeneity, and limited ADC diversity. DISCLOSURES: This study was supported by the National Institutes of Health/National Cancer Institute's Cancer Center Support Grant P30 CA008748. Several authors reported receiving personal fees and research funding from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
